Collaborating Across the Continuum™: Managing Relapsing MS – A Focus on the Utility of CD20-Targeted B-Cell Therapy

Release Date: November 30, 2022
Expiration Date: November 30, 2023

Stephen Krieger, MD, FAAN
Jacci Bainbridge, PharmD, FCCP
Denise Bruen, ANP-BC, MSN, MSCN

Activity Overview

Following the success of anti-CD20 antibodies in the treatment of multiple sclerosis (MS), there has been a shift in understanding of its pathophysiology. B cells have been identified as playing a key role in triggering MS disease activity, although it remains unclear which intercepted B-cell function is most relevant in this context. These advances in understanding of the immune mechanisms have led to the development of many immunotherapeutic drugs that target B cells. For example, there have been successful trials for 4 anti-CD20 monoclonal antibodies in patients with MS, showing that B-cell depletion can be an effective treatment for the relapsing subtype. This activity will focus on developments in understanding the role of B cells in the pathogenesis of MS, emerging therapies, and strategies for developing personalized care to improve outcomes and quality of life for patients with relapsing MS (RMS).

Target Audience

This activity is intended for community neurologists, MS specialists, specialty nurse practitioners, physician assistants, registered nurses, pharmacists, and other members of the MS care team.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:

  • Describe the role of B cells in the pathogenesis of MS in order to better recognize potential targets for therapy
  • Analyze clinical trial data for current and emerging anti-CD20 monoclonal antibody therapies in order to optimize treatment choices for appropriate patients with RMS
  • Design individualized treatment plans for the optimal management of patients with RMS
Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.25 Contact Hours.

In support of improving patient care, this activity has been planned and implemented by The Consortium of Multiple Sclerosis Centers (CMSC) and Physicians’ Education Resource®, LLC. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The CMSC designates this knowledge-based activity (UAN # JA4008165-9999-22-040-H01-P) for 1.25 contact hours (.125 CEUs) of continuing pharmacy education credit.

Upon successful completion of the activity, your CE credits will be submitted electronically to the NABP CPE Monitor service. Paper certificates are not valid. For information about CPE Monitor, visit

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

About Me

The Continuing Medical Education Program is an integral part of the organization’s overall mission which aims to improve learners’ competence and performance‐in‐practice and ultimately improve patient outcomes.

Related Posts